Spin-out Companies

When you conduct research into diseases at cellular and molecular level, you can also discover new knowledge that may suggest other types of treatment. A number of researchers have established companies which are in the process of developing new medicines on the basis of their basic scientific research for the benefit of patients. Some of those are presented on this page.

In 2017, researchers from Draupnir Bio received DKK 10 million from the Novo Nordisk Foundation to develop a new type of cholesterol-lowering medicine which prevents blood clots in the heart more effectively than the current medicine.

Read more about Draupnir Bio

Many men with erectile dysfunction do not benefit from Viagra. Initiator Pharma went public on the stock exchange in 2017, and the researchers have secured SEK 38 million towards the development of a new type of medicine for these men.

Read more about Initiator Pharma

The focus of Muna Therapeutics research is to develop small molecules that can repair dysfunction in the brain's nerve cells and in this way curb different types of dementia. In 2021 the company raised a total of 450 million DKK (EUR 60 million) in funding for its research.

Read more about Muna Therapeutics

The researchers in NMD Pharma are trying to develop medicine for patients who cannot move due to poor connections between the nervous system and the muscles. A number of foundations have invested DKK 280 million in the company, which is one of the biggest investments in a Danish biotech company ever.

Read more about NMD Pharma


For more information about spin-out companies at the department, please contact our business engagement partner:

Claus Elsborg Olesen

Professor in Biomedical Innovation